The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags.
OBJECTIVE
The aim of this retrospective study was to determine the incidence of vinca alkaloid extravasation following administration via syringes or mini-bags.


METHODS
An electronic survey was sent to pharmacy departments at hospitals throughout Australia. The survey was designed to collect data on the administration methods of vinca alkaloids (vincristine, vinblastine, vinorelbine) and the corresponding documented incidence of extravasation. The questionnaire requested the following information: how the drugs were prepared for administration (syringe or mini-bag); volume of each product; number of items supplied; and the number of cases of extravasation reported for each product.


RESULTS
Questionnaires were sent to 228 hospital pharmacy departments in Australia. Sixty-eight questionnaires were received (29.8%), including responses from most major cancer centres. Data represented a range of 3 to 120 months (mean: 38 months) of clinical experience. The reported incidence of vincristine extravasation from syringes was 0.03% (11/37 084) and 0.041% (3/7255) with mini-bags. One case of vinblastine extravasation was reported with syringes 0.013% (1/7913), none from mini-bags (0/1421). Vinorelbine data were difficult to interpret as cases may represent phlebitis rather than extravasation. The reported incidence from vinorelbine syringes was 0.029% (2/6914) and 0.146% (8/5475) with mini-bags. Excluding vinorelbine data, the reported vinca alkaloid extravasation episodes from syringes (0.027%) and mini-bags (0.035%) were found to be similar and infrequent.


CONCLUSIONS
The data suggest that vinca alkaloids can be given safely as low volume, short infusions via mini-bags. Policies and practices that ensure the same careful monitoring of infusional therapy as is recommended with administration by syringe may further reduce the incidence of untoward effects. Mini-bags should be used for the administration of vinca alkaloids and this practice will prevent the inadvertent intrathecal administration of vinca alkaloids via syringes.
Gilbar
Peter J
PJ
Department of Pharmacy, Toowoomba Health Services, PMB 2, Toowoomba 4350, Australia. peter_gilbar@health.qld.gov.au
Carrington
Christine V
CV
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001315:Australia; D005119:Extravasation of Diagnostic and Therapeutic Materials; D006306:Health Surveys; D006801:Humans; D015994:Incidence; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D013594:Syringes; D014748:Vinca Alkaloids / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D014748:Vinca Alkaloids